Exelixis Inc. Stock
Price
Target price
€49.11
€49.11
1.190%
0.58
1.190%
€46.00
05.08.26 / Tradegate
WKN: 936718 / Symbol: EXEL / Name: Exelixis / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Exelixis Inc. Stock
Exelixis Inc. gained 1.190% today.
We see a rather positive sentiment for Exelixis Inc. with 18 Buy predictions and 1 Sell predictions.
However, we have a potential of -6.32% for Exelixis Inc. as the target price of 46 € is below the current price of 49.11 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Exelixis Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | 1.190% | 1.572% | 2.687% | 51.746% | 27.479% | 166.730% | 242.076% |
| Ligand Pharmaceuticals | 0.760% | 3.968% | -6.429% | 123.932% | 57.831% | 329.508% | 184.103% |
| United Therapeutics | 0.820% | -1.964% | -7.722% | 70.448% | 5.149% | 109.366% | 158.218% |
| Ionis Pharmaceuticals Inc. | 0.520% | -0.614% | -34.392% | 26.102% | -30.974% | 29.981% | 40.998% |
Comments
Exelixis (EXEL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $56.00 price target on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (EXEL) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (EXEL) had its price target raised by HC Wainwright from $54.00 to $56.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
News
Exelixis Q2 Earnings Call Highlights
Key Points
- Interested in Exelixis, Inc.? Here are five stocks we like better.
- Q2 revenue reached approximately $629 million, driven by $573 million in U.S. cabozantinib franchise net product
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead
If you had invested in Krystal Biotech (NASDAQ: KRYS), Exelixis (NASDAQ: EXEL), or CVS Health (NYSE: CVS) at the beginning of the year, you'd be sitting pretty. All three companies have outpaced the
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near
Key Points
- Interested in Exelixis, Inc.? Here are five stocks we like better.
- Exelixis is leaning on CABO growth in renal cell carcinoma and neuroendocrine tumors, with management emphasizing